These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 10435877)
21. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T; Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489 [TBL] [Abstract][Full Text] [Related]
22. Blood 8-hydroxy-2'-deoxyguanosine is associated with erythropoietin resistance in haemodialysis patients. Kato A; Odamaki M; Hishida A Nephrol Dial Transplant; 2003 May; 18(5):931-6. PubMed ID: 12686667 [TBL] [Abstract][Full Text] [Related]
23. Inverse relationships between haemoglobin and ristocetin-induced platelet aggregation in haemodialysis patients under erythropoietin therapy. Borawski J; Rydzewski A; Mazerska M; Kalinowski M; Pawlak K; Mysliwiec M Nephrol Dial Transplant; 1996 Dec; 11(12):2444-8. PubMed ID: 9017620 [TBL] [Abstract][Full Text] [Related]
24. Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients. Braun J; Lindner K; Schreiber M; Heidler RA; Hörl WH Nephrol Dial Transplant; 1997 Jun; 12(6):1173-81. PubMed ID: 9198047 [TBL] [Abstract][Full Text] [Related]
25. Importance of iron supply for erythropoietin therapy. Sunder-Plassmann G; Hörl WH Nephrol Dial Transplant; 1995 Nov; 10(11):2070-6. PubMed ID: 8643170 [TBL] [Abstract][Full Text] [Related]
26. Influence of relative hypoparathyroidism on the responsiveness to recombinant human erythropoietin in hemodialysis patients. Hsu SP; Peng YS; Pai MF; Hung KY; Tsai TJ Blood Purif; 2003; 21(3):220-4. PubMed ID: 12784047 [TBL] [Abstract][Full Text] [Related]
27. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis. Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100 [TBL] [Abstract][Full Text] [Related]
28. Erythropoietin treatment in haemodialysis patients with iron overload. el-Reshaid K; Johny KV; Hakim A; Kamel H; Sebeta A; Hourani H; Kanyike FB Acta Haematol; 1994; 91(3):130-5. PubMed ID: 8091934 [TBL] [Abstract][Full Text] [Related]
29. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance. Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY; J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432 [TBL] [Abstract][Full Text] [Related]
30. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients. Lui SF; Wong KC; Li PK; Lai KN Am J Nephrol; 1992; 12(1-2):55-60. PubMed ID: 1415366 [TBL] [Abstract][Full Text] [Related]
31. Chloramine removal from water used in hemodialysis. Ward DM Adv Ren Replace Ther; 1996 Oct; 3(4):337-47. PubMed ID: 8914698 [TBL] [Abstract][Full Text] [Related]
32. Dynamics of the erythropoiesis stimulating agent resistance index in incident hemodiafiltration and high-flux hemodialysis patients. Marcelli D; Bayh I; Merello JI; Ponce P; Heaton A; Kircelli F; Chazot C; Di Benedetto A; Marelli C; Ladanyi E; Kroczak M; Stuard S; Grassmann A; Scatizzi L; Brand K; Canaud B Kidney Int; 2016 Jul; 90(1):192-202. PubMed ID: 27178833 [TBL] [Abstract][Full Text] [Related]
33. Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet. Allegra V; Martimbianco L; Vasile A Nephrol Dial Transplant; 1997 May; 12(5):924-32. PubMed ID: 9175044 [TBL] [Abstract][Full Text] [Related]
34. Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients? Sommerburg O; Grune T; Hampl H; Riedel E; van Kuijk FJ; Ehrich JH; Siems WG Nephrol Dial Transplant; 1998 Oct; 13(10):2583-7. PubMed ID: 9794564 [TBL] [Abstract][Full Text] [Related]
35. Impacts of recombinant human erythropoietin treatment during predialysis periods on the progression of chronic kidney disease in a large-scale cohort study (Co-JET study). Akizawa T; Saito A; Gejyo F; Suzuki M; Nishizawa Y; Tomino Y; Tsubakihara Y; Akiba T; Hirakata H; Watanabe Y; Kawanishi H; Bessho M; Udagawa Y; Aoki K; Uemura Y; Ohashi Y; Ther Apher Dial; 2014 Apr; 18(2):140-8. PubMed ID: 24720404 [TBL] [Abstract][Full Text] [Related]
36. Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990-1996. Cotter DJ; Thamer M; Kimmel PL; Sadler JH Kidney Int; 1998 Dec; 54(6):2129-39. PubMed ID: 9853279 [TBL] [Abstract][Full Text] [Related]
37. Which parameters affect cytosolic free calcium in polymorphonuclear leukocytes of haemodialysis patients? Kárpáti I; Seres I; Mátyus J; Ben T; Paragh G; Varga Z; Kakuk G Nephrol Dial Transplant; 2001 Jul; 16(7):1409-15. PubMed ID: 11427633 [TBL] [Abstract][Full Text] [Related]
39. Acute effects of recombinant human erythropoietin on plasma levels of proendothelin-1 and endothelin-1 in haemodialysis patients. Kang DH; Yoon KI; Han DS Nephrol Dial Transplant; 1998 Nov; 13(11):2877-83. PubMed ID: 9829494 [TBL] [Abstract][Full Text] [Related]
40. Erythropoietin for anaemia in haemodialysis patients: results of a maintenance study (the Canadian Erythropoietin Study Group). Muirhead N; Laupacis A; Wong C Nephrol Dial Transplant; 1992; 7(8):811-6. PubMed ID: 1325613 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]